ABEC breaks the 2,000L ‘plastic ceiling’ with 4,900L single-use bioreactor
ABEC says its latest offering has twice the working volume of the 2,000L bioreactor systems generally deemed to be the upper limit in single-use bioprocessing.
ABEC says its latest offering has twice the working volume of the 2,000L bioreactor systems generally deemed to be the upper limit in single-use bioprocessing.
Vancouver, Canada-based RepliCel is developing an autologous cell therapy to treat patients with baldness due to androgenetic alopecia.
Cell therapy firms will be able to authenticate the foetal bovie serum (FBS) they use through a testing programme launched by GE Healthcare and Oritain.